Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 11, 2014, Pages

  Yang, Zu Yao ^a   Liu, Li ^a   Mao, Chen ^a   Wu, Xin Yin ^a   Huang, Ya Fang ^a   Hu, Xue Feng ^a   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE; VASCULOTROPIN RECEPTOR; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFUSION RELATED REACTION; LEUKOPENIA; MAINTENANCE THERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; FEMALE; LUNG NEOPLASMS; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922246233     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009948.pub2     Document Type: Review

References (58)

1. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. Journal of Clinical Oncology 2007;25:5777-84.
2. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. Journal of Clinical Oncology 2010;28(6):911-7.
3. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet 2009;373(9674):1525-31.
4. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, et al.Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annals of Oncology 2008;19(2):362-9.
5. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of Clinical Oncology 2000;18(4):904-14.
6. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, et al.Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 2008;113(9):2512-7.
7. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. Journal of Thoracic Oncology 2008;3(11):1286-92.
8. Maione P, Mencoboni M, Carrozza F, Vigano MG, Gebbia V, Verusio C, et al.Addition of cetuximab (C) to gemcitabine (G) in elderly or performance status 2 (PS) patients (pts) with advanced non small-cell lung cancer (NSCLC): The calc1 randomised phase 2 trials. Annals of Oncology. 2008; Vol. 19:ix24-ix32.
9. Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer 2010;67(1):86-92.
10. NCT00085501. S0342: Paclitaxel, carboplatin, and cetuximab in treating patients with stage IIIB or stage IV non-small cell lung cancer. www.clinicaltrials.gov/show/NCT00085501.
11. NCT00097214. Carboplatin plus cetuximab for treatment of stage IIIB/IV non-small cell lung cancer (NSCLC). www.clinicaltrials.gov/show/NCT00097214.
12. NCT00103207. Cetuximab in treating patients with recurrent or stage IIIB or stage IV lung cancer. www.clinicaltrials.gov/show/NCT00103207.
13. NCT00112294. Study of taxane/carboplatin +/-cetuximab as first-line treatment for patients with advanced/metastatic non-small cell lung cancer. www.clinicaltrials.gov/show/NCT00112294.
14. NCT00118118. Cetuximab in treating patients with recurrent or progressive metastatic non-small cell lung cancer. www.clinicaltrials.gov/show/NCT00118118.
15. NCT00148798. Study of cisplatin/vinorelbine +/-cetuximab as first-line treatment of advanced non small cell lung cancer (FLEX). www.clinicaltrials.gov/show/NCT00148798.
16. NCT00165334. Cetuximab and vinorelbine in elderly subjects with lung cancer. www.clinicaltrials.gov/show/NCT00165334.
17. NCT00193453. Gemcitabine, docetaxel, and cetuximab in patients with unresectable advanced non-small cell lung cancer. www.clinicaltrials.gov/show/NCT00193453.
18. NCT00216203. Pemetrexed plus cetuximab in patients with recurrent non small cell lung cancer. www.clinicaltrials.gov/show/NCT00216203.
19. NCT00828841. Phase 2b study of cetuximab with platinum-based chemo as first line treatment of recurrent or advanced NSCLC. www.clinicaltrials.gov/show/NCT00828841.
20. NCT01004731. Study of anti-epidermal growth factor receptor (EGFr) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with stage IV lung cancer. www.clinicaltrials.gov/show/NCT01004731.
21. Pirker R, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, Park K, et al.FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [Abstract No. 3]. Journal of Clinical Oncology: ASCO annual meeting proceedings. 2008.
22. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. Journal of Clinical Oncology 2005;23(36):9089-96.
23. Rosell R, Ramlau R, Szczesna A, Daniel C, Bertrand M, Garcia AR, et al.Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and cinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC) [abstract]. European Journal of Cancer: ECCO III European Cancer Conference; 2003 Sept 21-25; Copenhagen, Denmark. 2003.
24. Spigel DR, Greco FA, Thompson DS, Webb C, Rubinsak J, Inhorn RC, et al. Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer. Clinical Lung Cancer 2010;11(3):198-203.
25. Stinchcombe TE, Bradford DS, Hensing TA, LaRocca RV, Saleh M, Evans T, et al. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Investigation 2010;28(2):208-15.
26. Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. Journal of Clinical Oncology 2005;23(34):8786-93.
27. Von Pawel J, Park K, et al.Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX). Journal of Clinical Oncology: ASCO annual meeting proceedings. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 June 2-6; Atlanta, GA. 2006.
28. NCT00946712. S0819: Carboplatin/paclitaxel with or without bevacizumab and/or cetuximab in stage IV or recurrent non-small cell lung cancer. www.clinicaltrials.gov/show/NCT00946712.
29. Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, et al.Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of Clinical Oncology 2011;29(17):2312-8.
30. Butts. Study of Gemcitabine/Platinum +/-Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/show/study/NCT00112346 2005.
31. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Annals of Internal Medicine 2011;154(1):37-49.
32. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology 2005;23(25):5900-9.
33. FDA. Final Labeling Text (bevacizumab). www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf (accessed 19 May 2012).
34. FDA. Gefitinib (marketed as Iressa) Information. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110473.htm (accessed 19 May 2012).
35. FDA 2010. Highlights for Prescribing Information (Tarceva). www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf (accessed 19 May 2012).
36. FDA. FDA Approves Erbitux to Treat Late-Stage Head and Neck Cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278894.htm (accessed 23 May 2012).
37. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006;24(28):4539-44.
38. McMaster University. GRADEpro 3.6. McMaster University, 2014.
39. Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Annals of Oncology 2004;15(3):419-26.
40. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, GRADE Working Group. Rating quality of evidence and strength of recommendations: What is "quality of evidence" and why is it important to clinicians?. British Medical Journal 2008;336(7651):995-8.
41. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, et al.Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. Journal of Clinical Oncology 2010;28(31):4747-54.
42. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. International Agency for Research on Cancer. Fast stats: most frequent cancers. www.globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (accessed 19 May 2012).
44. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010;60(5):277-300.
45. Kim ES, Mauer AM, William WN Jr, Tran HT, Liu D, Lee JJ, et al.A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009;115(8):1713-22.
46. Lin H, Jiang J, Liang X, Zhou X, Huang R. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70(1):57-62.
47. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106(3):861-5.
48. Miller AB HB, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207-14.
49. Mitsudomi T. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. The Lancet Oncology 2011;12(8):710-1.
50. National Cancer Institute. FDA Approval for Cetuximab. www.cancer.gov/cancertopics/druginfo/fda-cetuximab (accessed 23 May 2012).
51. Nieder C, Pawinski A, Dalhaug A, Andratschke N. A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiation Oncology 2012;7:3.
52. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology 2012;13(1):33-42.
53. Reeves TD, Hill EG, Armeson KE, Gillespie MB. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngology-Head and Neck Surgery 2011;144(5):676-84.
54. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
55. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine 2002;346(2):92-8.
56. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proceedings of the American Thoracic Society 2009;6(2):233-41.
57. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000;92(3):205-16.
58. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clinical Therapeutics 2010;32(3):437-53.